Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HNF4A | P41235 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6057969 | 0.85 | TSHR (0.43) | ATMTDP1TSHRALDH1A1HIF1A | |
| SCHEMBL9031753 | 0.83 | TDP1 (0.44) | ATMTDP1TSHRALDH1A1VCAM1 | |
| SCHEMBL10586114 | 0.83 | TDP1 (0.40) | ATMTDP1TSHRALDH1A1HIF1A | |
| SCHEMBL3391673 | 0.79 | CYP1A2 (0.45) | ATMTDP1TSHRALDH1A1HIF1A | |
| SCHEMBL7646920 | 0.79 | GPR35 (0.46) | ATMTDP1TSHRALDH1A1CYP1A2 | |
| SCHEMBL29701589 | 0.79 | GPR35 (0.46) | ATMTDP1TSHRALDH1A1CYP1A2 | |
| SCHEMBL944512 | 0.79 | TDP1 (0.44) | ATMTDP1TSHRALDH1A1HIF1A | |
| SCHEMBL30472770 | 0.79 | TDP1 (0.44) | ATMTDP1TSHRALDH1A1HIF1A | |
| SCHEMBL9031916 | 0.77 | ITGB1 (0.38) | ATMTDP1ALDH1A1HIF1AVCAM1 | |
| SCHEMBL28540089 | 0.77 | ATM (0.43) | ATMTDP1TSHRALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| EP-1940825-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034143-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| EP-1324981-B1 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050159457-A1 | Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | PAN WENXI (US) | 2005-07-21 | — | — | US | disclosed |
| US-6900231-B2 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1324981-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6521663-B2 | For oral administration or embedded or otherwise attached to medical devices for blood collection and/or treatment | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS | 2002-05-23 | — | — | US | disclosed |
| WO-2002028825-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-0470578-B1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KK (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5399553-A | Oral absorbability | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1995-03-21 | — | — | US | disclosed |
| US-5254685-A | Tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0470578-A1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159457-A1 | Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | F12, TFPI, PLG | ATM 847/4885TDP1 865/4885TSHR 2389/4885 |
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ABL1, ERBB2, CDK2 | ATM 362/4885TDP1 2300/4885TSHR 2110/4885 |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | TFPI, PLG, PLAT | ATM 1077/4885TDP1 1398/4885TSHR 2559/4885 |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | TFPI, F12, PLAT | ATM 864/4885TDP1 1312/4885TSHR 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.